comprehensive -WSS

comprehensive

author：focus 2025-09-06 01:57:38 - browse：89

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Vivek Ramaswamy made waves in the debate, much as in biotech

Wikipedia

WSS

Kellogg’s is going to war over Mexico’s nutrition label rules

Antivenom research: Lessons from HIV applied in search for universal antidote

Medicare inequities exacerbate Puerto Rico’s health disparities

FDA greenlights medical device to combat bladder issues

Republicans love RFK Jr. What's that tell us about health in 2024?

How the first Native Hawaiian psychiatrist helped diversify medicine

explore

comprehensive

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

United colonoscopy coverage change 'may cost lives,' doctors say

People can get long Covid without testing positive for virus: Study

Walensky prepares to leave CDC — and Congress — behind

Health officials lay out plans to cope with respiratory virus season

Supreme Court strikes down use of affirmative action

Study: Spinal cord stimulation helps patients with paralysis walk again

United colonoscopy coverage change 'may cost lives,' doctors say

How the drug

knowledge

How to make over

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

New documents shed light on MD Anderson Cancer Institute feud

Obesity drugs seen as possible treatment for liver disease MASH

Health officials lay out plans to cope with respiratory virus season

R1 RCM gets $5.8 billion buyout offer from private equity firm

explore

explore

Wikipedia

focus